Trium Capital LLP Intra Cellular Therapies, Inc. Transaction History
Trium Capital LLP
- $801 Million
- Q1 2025
A detailed history of Trium Capital LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Trium Capital LLP holds 102,105 shares of ITCI stock, worth $13.5 Million. This represents 1.68% of its overall portfolio holdings.
Number of Shares
102,105Holding current value
$13.5 Million% of portfolio
1.68%Shares
1 transactions
Others Institutions Holding ITCI
# of Institutions
413Shares Held
87.3MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.28 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$834 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$676 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$428 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$424 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...